Samrat Pharma

Market Cap: Micro Cap
Industry: Pharmaceuticals & Biotechnology
ISIN: INE103E01016
NSEID:
BSEID: 530125

INR

257.00

4.7 (1.86%)

BSENSE

Dec 05

BSE+NSE Vol: 427

{
  "main_header": {
    "sid": 116063,
    "name": "Samrat Pharma",
    "stock_name": "Samrat Pharma",
    "full_name": "Samrat Pharmachem Ltd",
    "name_url": "stocks-analysis/samrat-pharma",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "257.00",
    "chg": 4.7,
    "chgp": "1.86%",
    "dir": 1,
    "prev_price": "252.30",
    "mcapval": "78.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 530125,
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE103E01016",
    "curr_date": "Dec 05",
    "curr_time": "",
    "bse_nse_vol": "427 ",
    "exc_status": "Active",
    "traded_date": "Dec 05, 2025",
    "traded_date_str": "2025 12 05",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/samrat-pharma-116063-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0,
      "all_data": []
    }
  },
  "news": {
    "results": [
      {
        "title": "Samrat Pharmachem Stock Falls to 52-Week Low of Rs.250",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/samrat-pharmachem-stock-hits-52-week-low-amidst-continued-underperformance-3738337",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/SamratPharmache_priceRelatedfactors_3738337.png",
        "date": "2025-12-01 11:08:07",
        "description": "Samrat Pharmachem's shares reached a fresh 52-week low of Rs.250 today, marking a significant decline amid broader market gains. The stock underperformed its sector and key benchmarks, reflecting ongoing pressures within the Pharmaceuticals & Biotechnology space."
      },
      {
        "title": "Samrat Pharmachem Stock Falls to 52-Week Low of Rs.251 Amidst Prolonged Underperformance",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/samrat-pharmachem-stock-hits-52-week-low-amidst-continued-underperformance-3731424",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/SamratPharmache_priceRelatedfactors_3731424.png",
        "date": "2025-11-26 12:46:33",
        "description": "Samrat Pharmachem’s shares touched a fresh 52-week low of Rs.251 today, marking a significant price level amid a year of sustained underperformance relative to the broader market and sector peers."
      },
      {
        "title": "Why is Samrat Pharma falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-samrat-pharma-fallingrising-3729727",
        "imagepath": "",
        "date": "2025-11-26 00:49:05",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Recent Price Movement and Market Performance</strong></p>\n<p>Samrat Pharmachem’s shares have been under pressure, registering a decline of 1.54% on 25 November, with the stock opening lower by 2.56% and touching an intraday low of ₹255.10, representing a 5.22% drop from recent levels. This decline extends a four-day losing streak during which the stock has fallen by 3.51%. The current price is just 4.68% above its 52-week low of ₹252.60, signalling proximity to its weakest levels in the past year.</p>\n<p>When compared to the broader market, the stock’s performance has been notably weak. Over the past week, Samrat Pharmachem declined by 1.56%, while the Sensex marginally dipped by 0.10%. The divergence becomes more pronounced over longer periods: the stock has lost 10.23% in the last month, w..."
      },
      {
        "title": "Samrat Pharmachem Falls to 52-Week Low of Rs.265 Amidst Continued Downtrend",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/samrat-pharmachem-stock-hits-52-week-low-amidst-continued-downtrend-3725710",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/SamratPharmache_priceRelatedfactors_3725710.png",
        "date": "2025-11-24 14:36:34",
        "description": "Samrat Pharmachem’s stock price reached a fresh 52-week low of Rs.265 today, marking a significant decline amid ongoing downward momentum. The pharmaceutical and biotechnology company’s shares have been under pressure, reflecting a series of financial and market challenges over the past year."
      },
      {
        "title": "Samrat Pharmachem Stock Falls to 52-Week Low of Rs.266.1 Amidst Continued Downtrend",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/samrat-pharmachem-stock-falls-to-52-week-low-of-rs2661-on-20-nov-2025-3717941",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/SamratPharmache_priceRelatedfactors_3717941.png",
        "date": "2025-11-20 11:12:55",
        "description": "Samrat Pharmachem has reached a new 52-week low of Rs.266.1 today, marking a significant decline in its stock price amid a broader market rally. The pharmaceutical company’s shares have slipped below all major moving averages, reflecting persistent pressures on its valuation and performance over the past year."
      },
      {
        "title": "Is Samrat Pharma overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-samrat-pharma-overvalued-or-undervalued-3713538",
        "imagepath": "",
        "date": "2025-11-19 08:07:42",
        "description": "As of 18 November 2025, the valuation grade for Samrat Pharma has moved from very attractive to very expensive, indicating a significant shift in its market perception. The company is currently considered overvalued. Key ratios reveal a PE Ratio of 53.48, an EV to EBITDA of 18.52, and a Price to Book Value of 1.18, all of which suggest that the stock is priced at a premium compared to its earnings and assets.\n\nIn comparison to its peers, Samrat Pharma's PE Ratio is notably higher than Sun Pharma's 36.56 and significantly exceeds Cipla's more attractive valuation at 22.49. Additionally, while the PEG Ratio stands at 0.00, indicating no growth expectations priced in, other competitors like Divi's Lab show a PEG of 1.96, reflecting a more balanced valuation. The company's recent stock performance has been poor, with a year-to-date return of -29.33%, contrasting sharply with the Sensex's gain of 8.36%, further ..."
      },
      {
        "title": "Is Samrat Pharma overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-samrat-pharma-overvalued-or-undervalued-3709696",
        "imagepath": "",
        "date": "2025-11-18 08:19:08",
        "description": "As of 17 November 2025, the valuation grade for Samrat Pharma has moved from attractive to very attractive, indicating a significant improvement in its perceived value. The company is currently deemed undervalued, particularly when considering its PE ratio of 53.08, EV to EBITDA of 22.76, and a Price to Book Value of 1.15. These ratios suggest that despite a high PE, the overall valuation metrics reflect a favorable position relative to its peers.\n\nIn comparison to notable competitors, Sun Pharma has a PE ratio of 36.69 and an EV to EBITDA of 24.22, while Divi's Lab is significantly more expensive with a PE of 69.78 and an EV to EBITDA of 52.44. This positions Samrat Pharma favorably within the industry, especially given its PEG ratio of 0.00, indicating potential for growth without the corresponding valuation pressure seen in its peers. Despite recent underperformance against the Sensex, with a year-to-dat..."
      },
      {
        "title": "How has been the historical performance of Samrat Pharma?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-samrat-pharma-3708548",
        "imagepath": "",
        "date": "2025-11-17 22:54:41",
        "description": "Answer:\nThe historical performance of Samrat Pharma shows a fluctuating trend in key financial metrics over the years.\n\nBreakdown:\nSamrat Pharma's net sales increased from INR 137.45 crore in March 2020 to INR 285.86 crore in March 2025, with a peak of INR 310.65 crore in March 2023. However, there was a decline in net sales from March 2023 to March 2024, followed by a slight recovery in March 2025. The total operating income mirrored this trend, reaching INR 310.65 crore in March 2023 before dropping to INR 281.58 crore in March 2024 and rebounding to INR 285.86 crore in March 2025. The operating profit (PBDIT) saw significant fluctuations, peaking at INR 24.89 crore in March 2022, then dropping to INR 2.47 crore in March 2024, and recovering to INR 10.24 crore in March 2025. Profit after tax also exhibited volatility, with a high of INR 16.63 crore in March 2023, declining to INR 2.16 crore in March 2024,..."
      },
      {
        "title": "Samrat Pharmachem Stock Plummets to 52-Week Low of Rs. 266.55",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/samrat-pharmachem-stock-plummets-to-52-week-low-of-rs-26655-3707001",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/SamratPharmache_priceRelatedfactors_3707001.png",
        "date": "2025-11-17 10:40:20",
        "description": "Samrat Pharmachem has reached a new 52-week low, reflecting ongoing challenges in the market. The company's stock has declined significantly over the past year, underperforming compared to the broader market. Despite a historical growth in operating profits, recent financial results indicate a notable decrease in profitability."
      }
    ],
    "total": 5725,
    "sid": "116063",
    "stock_news_url": "https://www.marketsmojo.com/news/samrat-pharmachem-116063"
  },
  "announcements": [
    {
      "caption": "Announcement under Regulation 30 (LODR)-Credit Rating",
      "datetime": "02-Dec-2025",
      "details": "Crisil Ltd has downgraded its rating to CrisilBB+/Negative/CrisilA4+",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
      "datetime": "20-Nov-2025",
      "details": "Newspaper Publication - Extract of Results for the quarter and half year ended September 30 2025",
      "source": "BSE"
    },
    {
      "caption": "Board Meeting Outcome for Outcome Of Board Meeting Held Today",
      "datetime": "14-Nov-2025",
      "details": "The Board of Directors considered and took on record the Un-audited Standalone Financial Results for the quarter and half year ended September 30 2025.",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Samrat Pharmachem Ltd has declared <strong>10%</strong> dividend, ex-date: 18 Sep 25",
          "dt": "2025-09-18",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Samrat Pharmachem Stock Falls to 52-Week Low of Rs.250

2025-12-01 11:08:07

Samrat Pharmachem's shares reached a fresh 52-week low of Rs.250 today, marking a significant decline amid broader market gains. The stock underperformed its sector and key benchmarks, reflecting ongoing pressures within the Pharmaceuticals & Biotechnology space.

Samrat Pharmachem Stock Falls to 52-Week Low of Rs.251 Amidst Prolonged Underperformance

2025-11-26 12:46:33

Samrat Pharmachem’s shares touched a fresh 52-week low of Rs.251 today, marking a significant price level amid a year of sustained underperformance relative to the broader market and sector peers.

Why is Samrat Pharma falling/rising?

2025-11-26 00:49:05

Recent Price Movement and Market Performance

Samrat Pharmachem’s shares have been under pressure, registering a decline of 1.54% on 25 November, with the stock opening lower by 2.56% and touching an intraday low of ₹255.10, representing a 5.22% drop from recent levels. This decline extends a four-day losing streak during which the stock has fallen by 3.51%. The current price is just 4.68% above its 52-week low of ₹252.60, signalling proximity to its weakest levels in the past year.

When compared to the broader market, the stock’s performance has been notably weak. Over the past week, Samrat Pharmachem declined by 1.56%, while the Sensex marginally dipped by 0.10%. The divergence becomes more pronounced over longer periods: the stock has lost 10.23% in the last month, w...

Samrat Pharmachem Falls to 52-Week Low of Rs.265 Amidst Continued Downtrend

2025-11-24 14:36:34

Samrat Pharmachem’s stock price reached a fresh 52-week low of Rs.265 today, marking a significant decline amid ongoing downward momentum. The pharmaceutical and biotechnology company’s shares have been under pressure, reflecting a series of financial and market challenges over the past year.

Samrat Pharmachem Stock Falls to 52-Week Low of Rs.266.1 Amidst Continued Downtrend

2025-11-20 11:12:55

Samrat Pharmachem has reached a new 52-week low of Rs.266.1 today, marking a significant decline in its stock price amid a broader market rally. The pharmaceutical company’s shares have slipped below all major moving averages, reflecting persistent pressures on its valuation and performance over the past year.

Is Samrat Pharma overvalued or undervalued?

2025-11-19 08:07:42

As of 18 November 2025, the valuation grade for Samrat Pharma has moved from very attractive to very expensive, indicating a significant shift in its market perception. The company is currently considered overvalued. Key ratios reveal a PE Ratio of 53.48, an EV to EBITDA of 18.52, and a Price to Book Value of 1.18, all of which suggest that the stock is priced at a premium compared to its earnings and assets. In comparison to its peers, Samrat Pharma's PE Ratio is notably higher than Sun Pharma's 36.56 and significantly exceeds Cipla's more attractive valuation at 22.49. Additionally, while the PEG Ratio stands at 0.00, indicating no growth expectations priced in, other competitors like Divi's Lab show a PEG of 1.96, reflecting a more balanced valuation. The company's recent stock performance has been poor, with a year-to-date return of -29.33%, contrasting sharply with the Sensex's gain of 8.36%, further ...

Is Samrat Pharma overvalued or undervalued?

2025-11-18 08:19:08

As of 17 November 2025, the valuation grade for Samrat Pharma has moved from attractive to very attractive, indicating a significant improvement in its perceived value. The company is currently deemed undervalued, particularly when considering its PE ratio of 53.08, EV to EBITDA of 22.76, and a Price to Book Value of 1.15. These ratios suggest that despite a high PE, the overall valuation metrics reflect a favorable position relative to its peers. In comparison to notable competitors, Sun Pharma has a PE ratio of 36.69 and an EV to EBITDA of 24.22, while Divi's Lab is significantly more expensive with a PE of 69.78 and an EV to EBITDA of 52.44. This positions Samrat Pharma favorably within the industry, especially given its PEG ratio of 0.00, indicating potential for growth without the corresponding valuation pressure seen in its peers. Despite recent underperformance against the Sensex, with a year-to-dat...

How has been the historical performance of Samrat Pharma?

2025-11-17 22:54:41

Answer: The historical performance of Samrat Pharma shows a fluctuating trend in key financial metrics over the years. Breakdown: Samrat Pharma's net sales increased from INR 137.45 crore in March 2020 to INR 285.86 crore in March 2025, with a peak of INR 310.65 crore in March 2023. However, there was a decline in net sales from March 2023 to March 2024, followed by a slight recovery in March 2025. The total operating income mirrored this trend, reaching INR 310.65 crore in March 2023 before dropping to INR 281.58 crore in March 2024 and rebounding to INR 285.86 crore in March 2025. The operating profit (PBDIT) saw significant fluctuations, peaking at INR 24.89 crore in March 2022, then dropping to INR 2.47 crore in March 2024, and recovering to INR 10.24 crore in March 2025. Profit after tax also exhibited volatility, with a high of INR 16.63 crore in March 2023, declining to INR 2.16 crore in March 2024,...

Samrat Pharmachem Stock Plummets to 52-Week Low of Rs. 266.55

2025-11-17 10:40:20

Samrat Pharmachem has reached a new 52-week low, reflecting ongoing challenges in the market. The company's stock has declined significantly over the past year, underperforming compared to the broader market. Despite a historical growth in operating profits, recent financial results indicate a notable decrease in profitability.

View All News

Announcement

Announcement under Regulation 30 (LODR)-Credit Rating

02-Dec-2025 | Source : BSE

Crisil Ltd has downgraded its rating to CrisilBB+/Negative/CrisilA4+

Announcement under Regulation 30 (LODR)-Newspaper Publication

20-Nov-2025 | Source : BSE

Newspaper Publication - Extract of Results for the quarter and half year ended September 30 2025

Board Meeting Outcome for Outcome Of Board Meeting Held Today

14-Nov-2025 | Source : BSE

The Board of Directors considered and took on record the Un-audited Standalone Financial Results for the quarter and half year ended September 30 2025.